KHKen-Ichi Harada

Ken-Ichi Harada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ken-Ichi Harada has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparação entre LABicELISA e kit ELISA comercial para análise de microcistinas em águas

    by Cássia Reika Takabayashi Yamashita, Emília Kiyomi Kuroda, Josemarque Lima Da Rosa, Ken-Ichi Harada, Osamu Kawamura, Elisa Yoko Hirooka

    Os potenciais riscos associados à exposição às microcistinas (MCs) requerem o desenvolvimento de pesquisas voltadas para métodos de análise visando ao monitoramento eficiente e rápido de águas. O trabalho avaliou a aplicação dos imunoensaios ELISA desenvolvido em laboratório (LABicELISA) e o comercial (kit ELISA) para detecção de MCs em águas (n=22). O LABicELISA demonstrou ser mais sensível que o kit ELISA, apresentando limite de quantificação de 0,05 e 0,12 µg.L-1, respectivamente. Os resultados demonstraram que ambos os imunoensaios foram eficientes para detecção e análise de MCs em diferentes tipos de água (sintéticas, de mananciais destinados ao abastecimento e de reservatórios), com coeficiente de correlação de 0,997 e forte correlação na exatidão e precisão. O emprego do LABicELISA proporcionou análise com custo aproximado e reduzido de 100 vezes em relação ao do kit ELISA, podendo assim, aplicar em larga escala de abrangência para monitoramento de mananciais superficiais no país.

  • Quantitative Analytical Method for Determining the Levels of Gastric Inhibitory Polypeptides GIP1–42 and GIP3–42 in Human Plasma Using LC–MS/MS/MS

    by Atsushi Miyachi, Takayo Murase, Yuichiro Yamada, Takeshi Osonoi, Ken-Ichi Harada

    Gastric inhibitory polypeptide (GIP), an incretin, is an important subject in endocrinology. Some LC–MS assays have been proposed; however, their sensitivities are insufficient for the study of endogenous human incretin. Here, we describe a nanoflow LC hybrid triple quadrupole/linear ion trap MS assay for the simultaneous quantification of GIP1–42 and GIP3–42 from human plasma. We selected the surrogate peptide to avoid oxidative modification, and the endoproteinase Asp-N was selected for the proteolysis of GIP1–42 and GIP3–42. The phenylalanine residue at position 6 in both GIP1–42 and GIP3–42 was substituted with 13C9,15N-labeled phenylalanine, and these substituted GIPs were used as the internal standards. This facilitated accurate and precise quantification because large corrections are possible at all steps of sample pretreatment and ionization efficiency. The lower limit of quantification was 1 pM for GIP1–42 and 10 pM for GIP3–42 by using 200 μL of plasma. Quantification of GIP1–42 and GIP3–42 in plasma from patients with type 2 diabetes was possible using this method, which included protein precipitation, Asp-N proteolysis, solid-phase extraction, nanoflow LC, and positive-ion multiple reaction monitoring cubed (MRM3) for GIP1–8, and MRM for GIP3–8 to achieve accurate, precise, and quantitative analysis that can be validated to support large clinical trials.


  • Simultaneous enantiomeric determination of MDMA and its phase I and phase II metabolites in urine by liquid chromatography–tandem mass spectrometry with chiral derivatization

    by Keiko Nakanishi, Munehiro Katagi, Kei Zaitsu, Noriaki Shima, Hiroe Kamata, Akihiro Miki, Hajime Kato, Ken-Ichi Harada, Hitoshi Tsuchihashi, Koichi Suzuki

    A liquid chromatography–electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) procedure was developed for the simultaneous determination of enantiomers of the prevalent designer drug 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and phase II metabolites in urine with chiral derivatization. The analytes in urine were directly derivatized with chiral Marfey’s reagent, N α- (5-fluoro-2,4-dinitrophenyl)-d-leucinamide, without extraction. The diastereomers of the N α-(2,4-dinitrophenyl)-d-leucinamide derivatives generated were determined by LC-MS/MS. Satisfactory chromatographic separation was achieved for the enantiomers of MDMA and its metabolites 3,4-methylenedioxyamphetamine, 4-hydroxy-3-methoxymethamphetamine (HMMA), HMMA glucuronide, and HMMA sulfate on a semimicro octadecylsilane column using linear gradient elution. With use of multiple reaction monitoring mode, the limits of detection of these analytes ranged from 0.01 to 0.03 μg/mL. Linear calibration curves were obtained for all enantiomers from 0.1 to 20 μg/mL in urine. The method showed sufficient reproducibility and quantitative ability. This is the first report of a simple LC-MS/MS-based analytical procedure with direct chiral derivatization in aqueous media that allows simultaneous enantiomeric determination of drugs and their metabolites, including glucuronide and sulfate derivatives.


  • Open Access

    Mass Spectrometric Studies of Peptides from Cyanobacteria under FAB MS/MS Conditions.

    by Kiyonaga Fujii, Tsuyoshi Mayumi, Kazuyoshi Noguchi, Tatsuki Kashiwagi, Satoko Akashi, Kaarina Sivonen, Kazuo Hirayama, Ken-Ichi Harada